Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cortisol is sometimes called the “stress hormone” because it helps your body respond to stress.
Corcept Therapeutics moves forward with a groundbreaking advertising campaign to increase awareness of Cushing’s by focusing on the results of recent research conducted by the company that shows that almost 25% of people with difficult-to-treat Type-2 diabetes may, in fact, have Cushing’s Syndrome, which could, also be the underlying cause of the diabetes.
It’s always fascinating to listen to two of the recognized experts and leading clinicians in Cushing’s disease discuss their experiences with the disease and patients. In this Live Talk session, Pituitary World New’s innovative program for education and awareness, Dr. Kevin Yuen and Dr. Lewis Blevins bring an intimate, revealing look at their approaches to Cushing’s disease and syndrome.
I’m happy to welcome Leslie Edwin, president of Cushing’s Support and Research Foundation (CSRF), to our microphones. The CSRF is a leading Cushing’s disease and syndrome patient support organization.
This study is available free. Just click on this link to download it. As a way of background, this is the second Phase 3 study for ISTURISA (osilodrostat). The first phase 3 study, LINC 3,
Here are links to Dr. Blevins’ discussion of five drugs to treat hypercortisolism.
In the last podcast in the series on the drugs available to manage hypercortisolism, Dr. Blevins discusses mifepristone, trade name Korlym®.
This is the fourth podcast in a series of five on medications to treat Cushing’s disease. Today Dr. Blevins discusses Pasireotide, trade names Signifor and Signifor LAR.
Our third podcast in the series is on osilodrostat (trade name Isturisa®), a drug approved by the FDA in the US and the European Medicines Agency (EMA) to treat hypercortisolism in patients who are not candidates for surgery or those that surgery did not work. In this podcast, Dr. BLevins takes us inside his clinical practice to share his experiences with the drug.
The second podcast in our series on the medical management of hypercortisolism focuses on the drug metyrapone. Dr. Blevins discusses the drug uses, how it works, and its side effects.
Coming up next, a discussion on the drug Isturiza® (osilodrostat).
This is the first in our series of five podcasts on the medical management of Hypercortisolism due to Cushing’s disease. Today Dr. Blevins discusses the drug Ketoconazole. Tune in tomorrow to listen to the second podcast in the series on the use of Metyrapone, and on Monday, don’t miss the podcast on Isturisa® (osilodrostat).
We are pleased to announce a series of podcasts on the medical management of hypercortisolism.